Abstract CT128: IMU-201-101 - an open-label, multi-center, dose escalation/expansion, phase 1 study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer

Authors: Pravin Kaumaya, Tanios Bekaii-Saab, Tri Phan, Mark T. Marino, Nick Ede, Anthony Good

Published: 2020-09-04

DOI: 10.1158/1538-7445.am2020-ct128

Source: Full article